Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $18.1 million.

  • Mirum Pharmaceuticals' Share-based Compensation rose 5222.54% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.6 million, marking a year-over-year increase of 4616.93%. This contributed to the annual value of $48.4 million for FY2024, which is 3832.05% up from last year.
  • According to the latest figures from Q3 2025, Mirum Pharmaceuticals' Share-based Compensation is $18.1 million, which was up 5222.54% from $18.5 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Share-based Compensation ranged from a high of $18.5 million in Q2 2025 and a low of $4.8 million during Q2 2021
  • Over the past 5 years, Mirum Pharmaceuticals' median Share-based Compensation value was $8.4 million (recorded in 2023), while the average stood at $9.8 million.
  • In the last 5 years, Mirum Pharmaceuticals' Share-based Compensation surged by 11630.69% in 2021 and then plummeted by 683.75% in 2022.
  • Over the past 5 years, Mirum Pharmaceuticals' Share-based Compensation (Quarter) stood at $5.6 million in 2021, then grew by 23.94% to $6.9 million in 2022, then skyrocketed by 40.95% to $9.7 million in 2023, then skyrocketed by 36.33% to $13.3 million in 2024, then soared by 36.8% to $18.1 million in 2025.
  • Its Share-based Compensation stands at $18.1 million for Q3 2025, versus $18.5 million for Q2 2025 and $15.8 million for Q1 2025.